[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342233-105":59,"doc-detail-342233-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","elongation-factor-2-in-cancer-a-promising-therapeutic-target-in-protein-translation","Elongation factor 2 in cancer - a promising therapeutic target in protein translation","","Aberrant elongation of proteins drives oncogenic signaling dysregulation and supports cancer progression. Eukaryotic elongation factor 2 (eEF2) is a key controller of protein synthesis, extending nascent peptides with high precision during translation. Although eEF2 dysregulation is linked to multiple cancers, prior work has emphasized structural aspects, leaving molecular functions insufficiently defined. This mini review summarizes advances in eEF2 structure, GTPase activity, posttranslational modifications, regulators, and inhibitors, outlining eEF2’s therapeutic potential and highlighting unanswered research questions for future studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elongation-factor-2-in-cancer-a-promising-therapeutic-target-in-protein-translation/342233/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elongation-factor-2-in-cancer-a-promising-therapeutic-target-in-protein-translation/342233.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does eEF2 play in protein translation?","Question",{"text":112,"@type":113},"Eukaryotic elongation factor 2 (eEF2) is an essential regulator that elongates nascent peptides by facilitating translation through GTP-dependent interactions and conformational changes during elongation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is eEF2 connected to cancer development?",{"text":117,"@type":113},"eEF2 is overexpressed in several cancers, and elevated levels are associated with increased incidence and poorer patient prognosis, contributing to tumor progression through translational dysregulation.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic strategies are discussed for targeting eEF2?",{"text":121,"@type":113},"The review summarizes inhibitors and regulatory mechanisms affecting eEF2, and it highlights a phase 1 trial using MOC31-PE as an immunotoxin designed to target EpCAM-positive carcinomas by inhibiting protein synthesis via eEF2 modification.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342233,1790337421,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Jia et al. Cellular & Molecular Biology Letters (2024) 29:156 [https://doi.org/10.1186/s11658-024-00674-7](https://doi.org/10.1186/s11658-024-00674-7)  \nCellular & Molecular Biology Letters  \nMINI REVIEW Open Access  \nElongation factor 2 in cancer: a promising therapeutic target in protein translation  \nXuechao Jia1,2†, Chuntian Huang1,3†, Fangfang Liu5*, Zigang Dong2,4,6,7* and Kangdong Liu2,4,6,7*  \n\n| †Xuechao Jia and Chuntian Huang have contributed equally to this work. |\n| --- |\n| *Correspondence:\u003Cbr>[ffliu89@zzu.edu.cn](ffliu89@zzu.edu.cn); dongzg@zzu. [edu.cn](edu.cn); [kdliu@zzu.edu.cn](kdliu@zzu.edu.cn) |\n\n1 Henan International Joint Laboratory of TCM Syndrome and Prescription in Signaling, Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China  \n2 Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, Henan, China  \n3 Department of Pathology and Pathophysiology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China  \n4 China-US (Henan) Hormel Cancer Institute, Zhengzhou 450000, Henan, China  \n5 Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450000, China  \n6 Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou 450001, Henan, China  \n7 The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou 450000, Henan, China  \nAbstract  \nAberrant elongation of proteins can lead to the activation of oncogenic signaling pathways, resulting in the dysregulation of oncogenic signaling pathways. Eukaryotic elongation factor 2 (eEF2) is an essential regulator of protein synthesis that precisely elongates nascent peptides in the protein elongation process. Although studies have linked aberrant eEF2 expression to various cancers, research has primarily focused on its structure, highlighting a need for deeper exploration into its molecular functions. In this review, recent advancements in the structure, guanosine triphosphatase (GTPase) activity, posttranslational modifications, regulatory factors, and inhibitors of eEF2 are summarized. These findings provide a comprehensive cognition on the critical role of eEF2 and its potential as a therapeutic target in cancer. Furthermore, this review highlights important unanswered questions that warrant investigation in future research. Keywords: Elongation factor 2, Cancer, Inhibitors, Protein elongation, Regulators  \nGraphical Abstract  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/.)[.](creativecommons.org/licenses/by/4.0/.)  \nIntroduction  \nTranslation elongation is tightly regulated by a complex network of factors, including ribosomal proteins, transfer RNA (tRNA) synthetases, and other factors. Dysregulation of these factors impacts protein translation and contributes to cancer development and progression [1]. The aberrant translated proteins subsequently induce the continuous activation of oncogenic signaling in cancer, leading to the dysregulating of both the onco","cbCaithcXgg0T9cN","https://ap.wps.com/l/cbCaithcXgg0T9cN","pdf",2158757,21,"English","# Abstract\n# Introduction\n## Translation elongation regulation and cancer\n## eEF2 structure, function, and clinical relevance\n## Therapeutic targeting of eEF2","[{\"question\":\"What role does eEF2 play in protein translation?\",\"answer\":\"Eukaryotic elongation factor 2 (eEF2) is an essential regulator that elongates nascent peptides by facilitating translation through GTP-dependent interactions and conformational changes during elongation.\"},{\"question\":\"How is eEF2 connected to cancer development?\",\"answer\":\"eEF2 is overexpressed in several cancers, and elevated levels are associated with increased incidence and poorer patient prognosis, contributing to tumor progression through translational dysregulation.\"},{\"question\":\"What therapeutic strategies are discussed for targeting eEF2?\",\"answer\":\"The review summarizes inhibitors and regulatory mechanisms affecting eEF2, and it highlights a phase 1 trial using MOC31-PE as an immunotoxin designed to target EpCAM-positive carcinomas by inhibiting protein synthesis via eEF2 modification.\"}]","Elongation factor 2 in cancer - a promising therapeutic target in protein translation | PDF",1790045862,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/049d3179cdc7681a5077ec8377e6ac48.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9732de82138f3c3af5c506ffaa44cc25.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0b8f94b2ab90428cb72c6f7c350727a.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bcaf38dce56fd3844c1f0aa6b600265.webp",980,1301]